Climb Bio, Inc.
NASDAQClimb Bio has surged 26% in a week, shorts are covering fast, and institutional money is flowing in — yet options traders are suddenly more defensive than at any point in recent memory. The positioning picture contains a genuine contradiction. Short interest has fallen sharply this week, down nearly 9% to 9.8% of the free float, and down from above 11% in early August. That move…
CLYM utilization hits 91.14%, near 52-week peak of 92.14% — shares to borrow extremely scarce relative to short interest.
Snapshot as of 12 Sept 2026
Climb Bio has surged 26% in a week, shorts are covering fast, and institutional money is flowing in — yet options traders are suddenly more defensive than at any point in recent memory. The positioning picture contains…
Climb Bio enters the back half of June with a 15% weekly gain, an unusually crowded call-side options book, and a wave of analyst conviction that stands in sharp contrast to a pipeline still in early clinical…
Climb Bio enters the week with the most notable analyst activity it has seen since its rebranding, as a fresh initiation from Guggenheim sets a price target that stands well above the rest of the Street. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CLYM — free to start on ORTEX.
Sign up for free →Open CLYM on ORTEX